Summary: Ascletis Pharma reported QQ2 2025 revenue of 540.5 million CNY, with a gross profit of 60.5 million CNY and a gross margin of 11.19%. Research and development expenses stood at 73.406 million CNY, while general and administrative expenses were 21.651 million CNY. Operating expenses totaled 95.058 million CNY, resulting in an EBITDA of -91.838 million CNY and an operating income of -94.996 million CNY. Net income totaled -43.976 million CNY, with earnings per share of -0.0457 CNY. The quarter benefited from a sizable other income line (51.021 million CNY) that modestly offset the operating loss, but the company remains loss-making at the net level as it continues to fund a broad R&D pipeline.
Liquidity remains robust with a current ratio of 14.57x, quick ratio of 14.53x, and cash ratio of 12.63x, while the debt load is negligible (debt ratio 0.214%). Cash per share stands at approximately 1.85 CNY against ~962.54 million weighted average shares. Despite the negative near-term profitability, Ascletis maintains substantial financial flexibility to advance its pipeline (HBV, HCV, cancer) and potential partnerships or licensing deals. Investors should note that outlook hinges on clinical readouts, regulatory progress, and milestones across ASC22, ASC40, ASC42/43 family, ASC60/ASC61/ASC63 programs, and other FDCs.
Overall, the QQ2 quarter reinforces Ascletis as a cash-rich, R&D-intensive biotech with a clear growth runway anchored in its multi-asset pipeline. The path to profitability remains contingent on successful clinical outcomes, strategic collaborations, and eventual product approvals.”